



HAL
open science

Impact of stress on cardiac phenotypes in mice harboring an ankyrin-B disease variant

Michael J Wallace, Nipun Malhotra, Juan Ignacio Elio Mariángelo, Tyler L Stevens, Lindsay J Young, Steve Antwi-Boasiako, Danielle Abdallah, Sarah Sumie Takenaka, Omer Cavus, Nathaniel P Murphy, et al.

► To cite this version:

Michael J Wallace, Nipun Malhotra, Juan Ignacio Elio Mariángelo, Tyler L Stevens, Lindsay J Young, et al.. Impact of stress on cardiac phenotypes in mice harboring an ankyrin-B disease variant. *Journal of Biological Chemistry*, 2023, 299 (6), pp.104818. 10.1016/j.jbc.2023.104818 . hal-04271860

HAL Id: hal-04271860

<https://hal.science/hal-04271860>

Submitted on 6 Nov 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2
3
4 **Impact of stress on cardiac phenotypes in mice harboring an ankyrin-B**
5
6 **disease variant**
7
8
9

10
11 Michael J. Wallace^{1,2}, Nipun Malhotra^{1,3}, Juan Ignacio Elio Mariángelo^{1,2}, Tyler L.
12 Stevens^{1,2}, Lindsay J. Young¹, Steve Antwi-Boasiako¹, Danielle Abdallah¹, Sarah
13 Sumie Takenaka¹, Omer Cavus¹, Nathaniel P. Murphy¹, Mei Han¹, Xianyao Xu¹,
14 Matteo E. Mangoni⁴, Thomas J. Hund^{1,5,6}, Jason D. Roberts⁷, Sandor Györke^{1,2},
15 Peter J. Mohler^{1,2,6} and Mona El Refaey^{1,3*}
16
17
18
19
20
21
22
23
24
25

26 ¹The Frick Center for Heart Failure and Arrhythmia, Dorothy M. Davis Heart and Lung
27 Research Institute, ²Department of Physiology and Cell Biology, ³Department of
28 Surgery/Division of Cardiac Surgery, The Ohio State University, Columbus, OH, USA.
29
30

31 ⁴Institut de Génomique Fonctionnelle, Université de Montpellier, CNRS, INSERM,
32 Montpellier, France.
33
34
35

36 ⁵Department of Biomedical Engineering, College of Engineering, The Ohio State
37 University, Columbus, Ohio, USA.
38
39
40

41 ⁶Department of Internal Medicine/Division of Cardiovascular Medicine, The Ohio
42 State University, Columbus, OH, USA.
43
44
45

46 ⁷Population Health Research Institute, McMaster University, and Hamilton Health
47 Sciences, Hamilton, Ontario, Canada.
48
49
50
51
52

53
54
55
56
57 **Running Title: Impact of stress on the phenotype of ankyrin-B syndrome**
58
59
60
61

1
2
3
4 ***Address correspondence to**
5

6
7 Mona El Refaey, PhD, MS
8

9
10 Department of Surgery/Division of Cardiac Surgery
11

12 The Dorothy M. Davis Heart and Lung Research Institute
13

14 The Ohio State University College of Medicine and Wexner Medical Center
15

16
17 333 West 10th Avenue, Columbus, OH, 43210
18

19
20 Mona.elrefaey@osumc.edu
21

22 Tel: 614-366-2748
23
24
25
26
27

28 **Keywords:** ankyrin-B, bradycardia, incomplete penetrance, heart rate variability,
29

30 fibrosis, arrhythmia, variant, heart failure, stress, cardiovascular disease.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

56 Total word count of the manuscript: 9453
57
58
59
60
61
62
63
64
65

1
2
3
4 **Abstract**
5
6

7
8 Encoded by *ANK2*, ankyrin-B (AnkB) is a multi-functional adaptor protein
9
10 critical for the expression and targeting of key cardiac ion channels, transporters,
11
12 cytoskeletal-associated proteins, and signaling molecules. Mice deficient for AnkB
13
14 expression are neonatal lethal and mice heterozygous for AnkB expression display
15
16 cardiac structural and electrical phenotypes. Human *ANK2* loss-of-function variants
17
18 are associated with diverse cardiac manifestations, however human clinical ‘ankyrin-
19
20 B syndrome’ displays incomplete penetrance. To date, animal models for human
21
22 arrhythmias have generally been knock-out or transgenic overexpression models and
23
24 thus the direct impact of *ANK2* variants on cardiac structure and function *in vivo* is
25
26 not clearly defined. Here, we directly tested the relationship of a single human *ANK2*
27
28 disease-associated variant with cardiac phenotypes utilizing a novel *in vivo* animal
29
30 model. At baseline, young AnkBp.E1458G^{+/+} mice lacked significant structural or
31
32 electrical abnormalities. However, aged AnkBp.E1458G^{+/+} mice displayed both
33
34 electrical and structural phenotypes at baseline including bradycardia and aberrant
35
36 heart rate variability, structural remodeling, and fibrosis. Young and old
37
38 AnkBp.E1458G^{+/+} mice displayed ventricular arrhythmias following acute
39
40 (adrenergic) stress. In addition, young AnkBp.E1458G^{+/+} mice displayed structural
41
42 remodeling following chronic (transverse aortic constriction) stress. Finally,
43
44 AnkBp.E1458G^{+/+} myocytes harbored alterations in expression and/or localization of
45
46 key AnkB-associated partners, consistent with the underlying disease mechanism. In
47
48 summary, our findings illustrate the critical role of AnkB in *in vivo* cardiac function as
49
50 well as the impact of single ankyrin-B loss-of-function variants *in vivo*. However, our
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 findings illustrate the contribution, and in fact necessity of secondary factors (aging,
5
6
7 adrenergic challenge, pressure-overload) to phenotype penetrance and severity.
8
9

10 **Introduction**

11
12
13 Ankyrin-B (AnkB), encoded by *ANK2*, was first identified to play a role in the
14
15 nervous system via maintenance of pre-myelinated axons (1), and subsequently
16
17 determined to impact cardiac function. AnkB regulates the expression and targeting
18
19 of key membrane, cytoskeletal, and regulatory proteins, including the Na⁺/Ca²⁺
20
21 exchanger (NCX), Na⁺/K⁺-ATPase (NKA), voltage-gated calcium channel (Ca_v1.3),
22
23
24 protein phosphatase 2 A (PP2A) and β-spectrin (2,3). *ANK2* encodes multiple
25
26 isoforms and is subject to transcriptional regulation (4).
27
28
29

30
31 AnkB dysfunction is associated with diverse human cardiac phenotypes,
32
33 including QT prolongation, arrhythmogenic cardiomyopathy (ACM), sinus node
34
35 dysfunction, and atrial fibrillation. Rare *ANK2* variants may also function as modifiers
36
37 of wall thickness in hypertrophic cardiomyopathy (5). The broad spectrum of AnkB
38
39 molecular partners in the heart likely accounts for the corresponding broad range of
40
41 cardiac phenotypes associated with *ANK2* dysfunction. The constellation of clinical
42
43 features observed with *ANK2* dysfunction has been termed 'ankyrin-B syndrome' (6-
44
45
46
47
48 10).
49

50
51 The human AnkBp.Glu1458Gly variant is associated with arrhythmias and
52
53 structural remodeling (7). However, ankyrin-B syndrome displays incomplete
54
55 penetrance, suggesting that AnkB variants alone may not be sufficient to directly
56
57 cause arrhythmia and/or structural phenotypes. Mouse gene knockout models may
58
59
60
61
62
63
64
65

1
2
3
4 not replicate human molecular phenotypes (e.g. in case of dominant-negative
5 variants). Therefore, we engineered a new animal model harboring the AnkB variant
6 p.E1458G. Here, we illustrate two points: 1, single ankyrin-B variants are sufficient to
7 cause cardiac phenotypes in six-month old AnkBp.E1458G^{+/+} mice, and 2, acute
8 and/or chronic stress augments the genesis of cardiac disease phenotypes in both
9 young and old mice carrying the human variant. Our findings support a role of single
10 *ANK2* variants in promoting mild cardiac phenotypes *in vivo*. However, severe *in vivo*
11 phenotypes require secondary stressors including aging and adrenergic-stress.
12
13
14
15
16
17
18
19
20
21
22
23

24 **Results**

25 **Generation of a novel humanized knock-in mouse model**

26
27
28
29
30
31 The AnkBp.E1458G variant (Figure 1A) is associated with ankyrin-B syndrome
32 (3) and ACM (7). To test if this variant is sufficient to induce cardiac phenotypes *in*
33 *vivo*, we generated a homozygous knock-in (KI) model (Figure 1B-C) harboring this
34 single amino acid substitution. Cas9 was used to introduce a double strand
35 chromosome break near codon 1371 in mouse (corresponds to 1458 in human
36 sequence, ENSMUST00000182078.9). A single stranded oligonucleotide donor was
37 used to change E1371 (E1458) to G1371 (G1458) and multiple silent coding changes
38 were also introduced to block the Cas9 targets. Sanger sequencing chromatograms
39 were used to confirm the substitution of glutamic acid (E) by glycine (G) in the KI
40 mouse (Figure 1B-C). AnkBp.E1458G^{+/+} mice were born at normal Mendelian ratios,
41 29% control mice (40/137), 46% heterozygous mice (63/137) and 25% homozygous
42 mice (34/137). *Ank2* mRNA expression levels were not changed in hearts of
43 AnkBp.E1458G^{+/+} mice compared to control littermates (Figure 1D). Canonical AnkB
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 protein levels were not significantly different between AnkBp.E1458G^{+/+} and control
5
6 littermate hearts (Figure 1E and F).
7
8

9 **Young AnkBp.E1458G^{+/+} mice do not display cardiac phenotypes**

10
11
12 Three-month old AnkBp.E1458G^{+/+} homozygous mice did not display structural
13 phenotypes. Specifically, three-month old AnkBp.E1458G^{+/+} mice did not display
14 changes in ejection fraction or fractional shortening (Figure 2A, Suppl. Figure 1A, G
15 and H). Moreover, AnkBp.E1458G^{+/+} mice did not exhibit electrocardiogram
16 alterations or arrhythmia phenotypes at three months of age (Suppl. Figure 2).
17
18
19
20
21
22
23
24

25 **Aged AnkBp.E1458G^{+/+} mice display structural remodeling and reduced 26 cardiac function**

27
28
29
30
31 AnkBp.E1458G^{+/+} mice showed a significant reduction in ejection fraction and
32 fractional shortening at ~six months of age (Figure 2B-D, Suppl. Figure 1B and Suppl.
33 Table 1). Six-month old AnkBp.E1458G^{+/+} mice also exhibited a trend towards an
34 increased LVID (p=0.0694, Suppl. Figure 1C) and decreased LVPW during systole
35 (p=0.0971, Suppl. Figure 1D) that did not reach statistical significance. No significant
36 changes were noted in LVID or LVPW during diastole (Suppl. Figure 1E-F). While
37 *Ank2*-cKO mice showed left ventricular dilation and increased body weight relative to
38 tibial length (7), these findings were not observed in the AnkBp.E1458G^{+/+} mice in
39 this study (Figure 2E-G). Notably, six-month old AnkBp.E1458G^{+/+} mice showed
40 widespread cardiac fibrosis at baseline compared with control mice (Figure 2F and
41 H). In summary, aged AnkBp.E1458G^{+/+} mice developed structural remodeling
42 characterized by cardiac fibrosis and reduced cardiac function in the absence of
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 stress. No significant changes were noted in the cardiac remodeling markers
5
6 including β -myosin heavy chain (*Myh7*), atrial natriuretic peptide (*Nppa*), brain
7
8 natriuretic peptide (*Nppb*), Collagen type I alpha 1 chain (*Col1a1*) and Tissue inhibitor
9
10 matrix metalloproteinase 1 (*Timp1*) in the AnkBp.E1458G^{+/+} mice at ~ six months of
11
12 age (Suppl. Figure 3).
13
14

15 16 17 **Aged AnkBp.E1458G^{+/+} mice exhibit electrical phenotypes** 18 19

20 Conscious six-month old AnkBp.E1458G^{+/+} mice exhibited sinus bradycardia
21
22 at rest (mean HR is 658.7±15.2 bpm in control mice vs. 590.5±21.58 bpm in
23
24 AnkBp.E1458G^{+/+} mice; Figure 3A and B; p=0.03). Accordingly, the RR interval was
25
26 significantly prolonged in the AnkBp.E1458G^{+/+} mice compared to the control
27
28 littermates (mean RR =0.0919 ± 0.0024 s in control mice vs. mean RR in
29
30 AnkBp.E1458G^{+/+} mice = 0.1035 ± 0.0040 s; Figure 3F; p=0.04). No significant
31
32 changes were noted in the P wave duration, PR interval or the QRS duration (Figure
33
34 3C-E and Suppl. Table 2). AnkBp.E1458G^{+/+} mice showed a statistically significant
35
36 prolongation in the QT-interval (mean= 0.0206 ± 0.0007 s in control mice vs. mean=
37
38 0.0231 ± 0.0006 s, p=0.02). However, the corrected QT interval (Mitchell et al. (11))
39
40 trended toward prolongation in the AnkBp.E1458G^{+/+} mice, but did not reach
41
42 statistical significance (mean= 0.0216 ± 0.0006 s in control mice vs. mean= 0.0228 ±
43
44 0.0007 s, p=0.25;Figure 3G and H). There is a debate on whether the QT interval is
45
46 affected by heart rate in small animals (12-14) and therefore, we measured both
47
48 intervals and displayed QTc according to Mitchell et al (11).
49
50
51
52
53
54
55

56
57 Abnormal high and low-frequency components of heart rate variability (HRV) may
58
59 suggest a dysfunction in autonomic regulation or an intrinsic sinus node dysfunction.
60
61

1
2
3
4 Specifically, the high frequency (HF) component is modulated by the
5
6 parasympathetic nervous system, while the low frequency (LF) reflects the activity of
7
8 both parasympathetic and sympathetic nervous system (15). The high- and low-
9
10 frequency spectral components of HRV were significantly increased in the
11
12 AnkBp.E1458G^{+/+} mice versus control littermates at rest (Figure 4A (p<0.01) and B
13
14 (p=0.02)) in line with mild bradycardia observed in AnkBp.E1458G^{+/+} mice. Notably,
15
16 LF/HF ratio was significantly reduced in the AnkBp.E1458G^{+/+} mice (Figure 4C
17
18 p=0.03). Analyzing the RR-interval of the control mice vs. the AnkBp.E1458G^{+/+} mice
19
20 over a 14 min interval confirmed and displayed both prolongation and variability in
21
22 the aged mice harboring the single amino acid substitution, AnkBp.E1458G. Analysis
23
24 of RR and standard deviation of RR (SDRR) intervals displayed a significant increase
25
26 in both parameters in the AnkBp.E1458G^{+/+} vs. the control mice (Figure 4D-E).
27
28 Representative traces from both genotypes over 1 min interval are displayed in
29
30 Figure 4F.
31
32
33
34
35
36
37
38

39 **AnkBp.E1458G^{+/+} mice exhibit arrhythmia in response to adrenergic challenge**

40
41
42 Previous studies using *Ank2*-cKO mice noted polymorphic arrhythmia events
43
44 following adrenergic stimulation (7). Young mice harboring the human variant
45
46 displayed an increase in the number of ventricular arrhythmic events (control,
47
48 mean~0.7 events vs. AnkBp.E1458G^{+/+} mice, mean ~18 events) (Figure 5A-D,
49
50 p=0.0325) when challenged with epinephrine. Moreover, six-month old mice also
51
52 showed a significant increase in the number of ventricular arrhythmia events
53
54 compared to their control littermates following epinephrine (control, mean ~14.5 ±
55
56 6.14 events and AnkBp.E1458G mice, mean ~35.8 ± 8.66 events) (Figure 6A,
57
58
59
60
61
62
63
64
65

1
2
3
4 p=0.04). Finally, when challenged with a stress protocol consisting of combined
5
6 epinephrine (2mg/kg) and caffeine (120mg/kg), the six-month old AnkBp.E1458G^{+/+}
7
8 mice displayed a significant increase in the number of ventricular arrhythmic events
9
10 (control, mean ~18.3 ± 6.34 events and AnkBp.E1458G mice, mean ~116.8 ± 41.73
11
12 events) (Figure 6B, p=0.04). Notably, the number and duration of sustained episodes
13
14 of ventricular tachycardia (VT) were significantly higher and prolonged in the
15
16 AnkBp.E1458G^{+/+} mice compared with control littermates (Figure 6C-D, p<0.01 and
17
18 p=0.03). The number of non-sustained ventricular tachycardia (NSVT) episodes
19
20 trended upward in AnkBp.E1458^{+/+} mice (Figure 6E, p=0.14). Representative
21
22 recordings denoting episodes of VT and NSVT are included in (Figure 6F-H). Taken
23
24 together, AnkBp.E1458G^{+/+} mice showed arrhythmic events following adrenergic
25
26 challenge or acute stressor at an early age. These events became more severe and
27
28 sustained in adult animals at six months of age.
29
30
31
32
33
34
35

36
37 Abnormal calcium handling may lead to cardiac electrical abnormalities either
38
39 through spontaneous calcium waves that cause delayed afterdepolarizations or
40
41 through calcium transient alternans, that provide a substrate for reentrant
42
43 mechanisms (16). In this study, we investigated calcium handling in cardiac myocytes
44
45 derived from AnkBp.E1458G^{+/+} mice and control littermates in the presence (100 nM
46
47 and 500 nM) and absence of isoproterenol (ISO). As expected, ISO significantly
48
49 increased the amplitude and rate of decay of calcium transients (Figure 7A-C). We
50
51 observed that the amplitude and rate of decay of calcium transients were similar
52
53 between AnkBp.E1458G^{+/+} and control myocytes ± ISO. Additionally, the frequency
54
55 of spontaneous calcium waves was comparable between the two groups (Figure 7D
56
57
58
59
60
61
62
63
64
65

1
2
3
4 and E). Notably, AnkBp.E1458G^{+/+} myocytes displayed a higher predisposition to
5
6 calcium transient alternans than WT myocytes (Figure 7F-H). In line with previous
7
8 studies (17,18), ISO tended to decrease the likelihood of alternans in WT myocytes.
9
10 However, in AnkBp.E1458G^{+/+} myocytes, ISO increased the predisposition to
11
12 alternans (Figure 7G-H). Overall, these findings illustrate calcium handling
13
14 dysfunction in AnkBp.E1458G^{+/+} myocytes.
15
16
17
18

19 **AnkBp.E1458G^{+/+} mice develop severe cardiac phenotypes in response to** 20 **chronic cardiac pressure overload** 21 22 23 24

25 We hypothesized that young AnkBp.E1458G homozygous mice would develop
26
27 an accelerated structural phenotype in response to chronic cardiac stress. Therefore,
28
29 a model of pressure overload, transverse aortic constriction (TAC), was performed in
30
31 young AnkBp.E1458G^{+/+} mice. AnkBp.E1458G^{+/+} mice exhibited a significant
32
33 reduction in contractility or ejection fraction and fractional shortening at eight and
34
35 twelve weeks post TAC compared to control littermates (Figure 8A and B). Moreover,
36
37 AnkBp.E1458G^{+/+} mice did not display significant differences in the LVID during
38
39 diastole or systole post TAC (Figure 8C-D). Furthermore, AnkBp.E1458G^{+/+} hearts
40
41 displayed widespread cardiac fibrosis in the homozygous hearts post TAC (Figure
42
43 8E and F) compared with control mice. Comparing the relative expression of cardiac
44
45 remodeling markers between the young mice (~2-3months of age) and mice post
46
47 TAC, no significant changes were noted in *Myh7*. We observed a significant increase
48
49 in *Nppa* relative expression in the control and AnkBp.E1458G^{+/+} hearts post TAC vs.
50
51 young control hearts (p=0.026 and p=0.025) and vs. young AnkBp.E1458G^{+/+} hearts
52
53 (p=0.032 and p=0.0036). *Nppb* relative expression was upregulated in the
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 AnkBp.E1458G^{+/+} hearts post TAC compared to the young controls (p=0.0168) and
5
6 young AnkBp.E1458G^{+/+} hearts (p=0.0125). *Col1a1* relative expression was
7
8 upregulated in the AnkBp.E1458G^{+/+} hearts post TAC compared to the young
9
10 AnkBp.E1458G^{+/+} (p=0.0467). Finally, *Timp1* was significantly upregulated in the
11
12 control (p=0.0382) and AnkBp.E1458G^{+/+} (p=0.0199) hearts post TAC compared to
13
14 young AnkBp.E1458G^{+/+} mice (Suppl. Figure 4).
15
16
17
18

19
20 **Expression and localization of AnkB membrane partners is altered in**
21
22 **AnkBp.E1458G^{+/+} hearts**
23
24

25 We investigated the expression of AnkB and AnkB-key binding partners,
26
27 including NCX and NKA, in our AnkBp.E1458G^{+/+} mouse model at baseline, older
28
29 age and post TAC. Immunoblotting experiments showed no changes in the
30
31 normalized expression of AnkB in the AnkBp.E1458G^{+/+} mice at six months of age
32
33 (Figure 9A and B). Additionally, *Ank2* mRNA levels were not different between the
34
35 two groups of mice at ~six months of age (Suppl. Figure 5). The expression of both
36
37 NCX and NKA was not different in the young AnkBp.E1458G^{+/+} mice at ~2 months of
38
39 age (Suppl. Figure 6A-D). The expression of NCX was not different between the
40
41 groups (Figure 9C and D) at ~six months of age. However, NKA protein expression
42
43 normalized to GAPDH showed a significant decrease in the hearts of the aged
44
45 AnkBp.E1458G^{+/+} mice (~30% reduction, p= 0.0023) (Figure 9E and F). Ankyrin-G
46
47 expression was unchanged between the two groups of mice (Figure 9G and Suppl.
48
49 Figure 7). Notably, NCX expression remained unchanged and the NKA expression
50
51 was significantly reduced in the AnkBp.E1458G^{+/+} mice post TAC compared to the
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 control mice (Suppl. Figure 6E-H). Finally, NKA protein was bound to the AnkB Ig in
5
6 the presence of the human variant (Suppl. Figure 8).
7
8
9

10 AnkB is a cytoskeletal protein that anchors and regulates the organization and
11
12 localization of both NKA and NCX in a macromolecular complex. We observed no
13
14 significant changes in the localization of NKA and NCX in AnkBp.E1458G^{+/+} isolated
15
16 myocytes in relation to ankyrin-B in young mice (Figure 10A-B, E-F). However,
17
18 immuno-labeling data in the aged AnkBp.E1458G^{+/+} myocytes demonstrated a
19
20 reduction in NKA localization at the T-tubules (Figure 10C, G). NCX signal was
21
22 consistently similar in the aged AnkBp.E1458G^{+/+} and control myocytes (Figure 10D,
23
24 H). In summary, six months old AnkBp.E1458G^{+/+} myocytes display altered NKA
25
26 expression and localization.
27
28
29
30
31

32 **Discussion**

33
34

35 The human AnkBp.E1458G variant was initially identified in a large French
36
37 family with a complex cardiac phenotype, including sinus node dysfunction,
38
39 ventricular arrhythmia, sudden cardiac death, and atrial fibrillation (6). This
40
41 phenotype, referred to as “AnkB-syndrome”, has been attributed to altered Ca²⁺
42
43 signaling when studied in a full-body haploinsufficient AnkB murine model (7,19). The
44
45 AnkBp.E1458G variant has also been implicated in other cardiac conditions, such as
46
47 ACM (5) and as a potential modifier of wall thickness in hypertrophic cardiomyopathy
48
49 (7). Notably, the same AnkBp.E1458G variant was identified by Hertz et al. in children
50
51 who suffered from sudden unexpected infant death (20,21). In summary, the range
52
53 of cardiac phenotypes identified to harbor the human AnkBp.E1458G variant are
54
55 diverse and complex.
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Despite numerous reports identifying the AnkBp.E1458G missense variant in
5 cases of cardiac disease, the variant has also been identified in non-diseased
6 populations, raising questions about its pathogenicity and penetrance (9,22).
7 Interestingly, Ware and colleagues reported that 49 of 64 published *ANK2* variants
8 were either “benign” or “probably benign” (23). AnkB plays a role in the transport and
9 localization of numerous proteins to the membrane, transverse-tubule, and
10 intercalated disc in cardiomyocytes. Although, the AnkBp.E1458G variant is not
11 located where AnkB associates with key binding partners, the variant is localized
12 close to the site critical for AnkB intramolecular association.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27 GnomAD data estimates the minor allele frequency of the AnkBp.E1458G AnkB
28 variant to be 0.000535 ([https://gnomad.broadinstitute.org/variant/4-114269433-A-](https://gnomad.broadinstitute.org/variant/4-114269433-A-G?dataset=gnomad_r2_1)
29 [G?dataset=gnomad_r2_1](https://gnomad.broadinstitute.org/variant/4-114269433-A-G?dataset=gnomad_r2_1)). Further, the AnkBp.E1458G variant is significantly more
30 prevalent among individuals with European and Latin ancestry. Therefore, it is more
31 frequent in the general population than the AnkB syndrome phenotype (24),
32 consistent with the incomplete penetrance of the AnkB phenotype associated with
33 the AnkBp.E1458G variant. These findings, coupled with the AnkBp.E1458G variant
34 most often being identified in sporadic cases of cardiac disease without clear
35 evidence of familial genotype-phenotype segregation, indicate that the variant must
36 rely on additional genetic and/or environmental factors in order to manifest with a
37 clinical phenotype.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 The translational relevance of the haploinsufficient and knockout mice has
55 previously been questioned given the strong mouse phenotype compared to the
56 commonly mild human phenotype, coupled with *ANK2* variants implicated in human
57
58
59
60
61
62
63
64
65

1
2
3
4 disease most often being missense (25). Recently, developments in gene editing
5
6 technology have allowed us to study the specific AnkBp.E1458G variant in mice, that
7
8 may more effectively model the human phenotype. The newly developed KI murine
9
10 model homozygous for the AnkBp.E1458G variant (Figure 1) provides a new tool and
11
12 new insights into the pathogenesis and penetrance of the AnkB syndrome.
13
14

15
16
17 Notably, aged AnkBp.E1458G^{+/+} mice displayed bradycardia (Figure 3) and
18
19 increased HF and LF spectral elements suggesting higher HR variability in mice at a
20
21 later age while the mice displayed a lower LF/HF ratio (Figure 4). Increase in HF and
22
23 LF is in line with lower basal heart rate observed in AnkBp.E1458G mice. The
24
25 increase in HRV seen in the KI mice might suggest an intrinsic sinus node dysfunction
26
27 associated with this variant that leads to increased heart variability as suggested by
28
29 a previous report (26). However, we cannot exclude that AnkBp.E1458G may also
30
31 present with increased activity of the parasympathetic nervous system. Additionally,
32
33 homozygous mice showed increased vulnerability to arrhythmic events in response
34
35 to adrenergic challenge as early as ~three months of age post adrenergic stimulation
36
37 (Figure 5). Aged mice showed propensity for more severe cardiac arrhythmic events,
38
39 more frequent events, and longer sustained runs of arrhythmic episodes in response
40
41 to adrenergic and caffeine administration (Figure 6). AnkBp.E1458G^{+/+} myocytes
42
43 displayed a higher a predisposition to calcium transient alternans that provides a
44
45 potential substrate for reentrant mechanisms (Figure 7). TAC surgery, a model for
46
47 chronic cardiac stress, also induced an accelerated heart failure phenotype in the
48
49 young AnkBp.E1458G^{+/+} mice (Figure 8). Overall, stress-inducing studies support our
50
51 hypothesis that the AnkBp.E1458G variant may be more likely to manifest with a
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 cardiac phenotype in response to environmental stressors and aging. Similar results
5
6 were reported in a truncated Plakophilin-2 (PKP2) mouse model (p.R735X).
7
8 Plakophilin 2 variants are the most common ACM-causing genetic variants,
9
10 accounting for 23-58% of all ACM cases. However, the ACM phenotype did not
11
12 manifest in the PKP2p.R735X transgenic mice until exposure to eight weeks of
13
14 endurance exercise training (another environmental stressor) (27,28).
15
16
17
18

19
20 Previous studies have shown NKA and AnkB dissociation as a prominent
21
22 mechanism for myocardial cell death after myocardial ischemia (29). Calpain-
23
24 mediated degradation of the NKA anchorage to the membrane cytoskeleton resulted
25
26 in Na^+ overload, which had a secondary effect on NCX resulting in secondary Ca^{2+}
27
28 overload within the cell following ischemia (29). Moreover, Skogestad et al. recently
29
30 demonstrated how disruption in the AnkB/NKA interaction resulted in increased Ca^{2+}
31
32 sparks (30). Inhibition of NKA raises $[\text{Na}^+]_i$, and therefore influences the function of
33
34 NCX. In order to extrude excess Na^+ , $[\text{Ca}^{2+}]_i$ becomes elevated, which can result in
35
36 altered Ca^{2+} cycling. Interestingly, Li et al. identified that inhibition of NKA during
37
38 stressed conditions can elicit pro-arrhythmic alternans in guinea pig cardiomyocytes
39
40 (31). Increased $[\text{Ca}^{2+}]_i$ may result in calcium alternans that may translate into
41
42 conduction block and reentrant arrhythmia via non-uniform refractoriness throughout
43
44 the electrical signaling pathways (32).
45
46
47
48
49
50

51
52 There are limitations to our work. Affected individuals in the setting of
53
54 AnkBp.E1458G have been in the heterozygous state. Notably, the phenotype of the
55
56 heterozygous mouse models (usually haploinsufficient) for desmosomal variants are
57
58 modest (often nothing is observed) and hence desmosomal genetic culprits are also
59
60
61

1
2
3
4 frequently studied in the homozygous state (33). Although gene dosage may be
5
6 higher, this mouse model still serves as an effective model for evaluating the potential
7
8 pathologies associated with this AnkB variant. A pressure overload model has not
9
10 previously been shown to predispose to ACM and to our knowledge, there is no
11
12 clinical data to suggest that pressure overload or hypertension exacerbates clinical
13
14 phenotype in the setting of an *ANK2* variant. Conclusions from this study should be
15
16 extrapolated with caution to other pathogenic human *ANK2* variants. Gene delivery
17
18 and pharmacological therapeutics can both be tested *in vivo* using this knock-in
19
20 model. While our studies were performed *in vivo*, it will be still crucial for expansion
21
22 of these studies into large animal models. Human induced pluripotent stem cells
23
24 (iPSCs) would best allow for specific excitation-contraction coupling and further Ca²⁺
25
26 regulation studies. In summary, while *ANK2* variants may be loss of function in vitro
27
28 or even in animal models, our findings support that secondary genetic or
29
30 environmental factors should be carefully assessed in the context of an ultimate
31
32 human clinical phenotype.
33
34
35
36
37
38
39
40

41 **Experimental Procedures**

42 **Mice**

43
44
45 A knock-in (KI) mouse to mimic the human variant at amino acid 1458 of human
46
47 *ANK2* was generated by The University of Michigan Transgenic Animal Model Core.
48
49 A single guide RNA (gRNA) was designed to create a CRISPR-induced indel in a
50
51 region close to codon 1371 in mouse (which corresponds to 1458 in human
52
53 sequence, ENSMUST00000182078.9). The gRNA along with Cas9 were
54
55 microinjected into C57BL/6J and SJL/J zygotes. Chimera mice were screened for the
56
57
58
59
60
61
62
63
64
65

1
2
3
4 single amino acid substitution at the guide sequence. Germline mice were generated
5
6 by breeding chimeras to C57BL6/J mice. After germline transmission, mice were
7
8 genotyped and sequenced to confirm the substitution of the Glutamic acid amino acid
9
10 (E) for Glycine (G) (Forward: TGTAGACCAGTCCACCAGACACATT; Reverse:
11
12 CCCTGTCTAATTTCTCTAAAGTCAGAGGC). Mice were backcrossed on a
13
14 C57BL/6 background for five generations. The whole colony was produced from a
15
16 single founder. Age-matched male and female mice were used in experiments
17
18 throughout the manuscript. All animal experiments were conducted in accordance
19
20 with the Ohio State University Institutional Animal Care and Use Committee
21
22 guidelines (IACUC Protocol Number 2011A00000034).
23
24
25
26
27
28

29 **Echocardiography**

30
31
32 Transthoracic echocardiography using (GE Logiq e) with the L10-22 (mHz)
33
34 transducer was performed on mice anesthetized using 2% isoflurane in 95% O₂ and
35
36 5% CO₂. Anesthesia was maintained by administration of oxygen and approximately
37
38 1.25% isoflurane during the whole imaging procedure. Heart rate (HR) was monitored
39
40 throughout imaging and recordings taken at a HR less than 400bpm were excluded
41
42 from the analysis. Mice were immobilized on a heated imaging stage during image
43
44 acquisition and a temperature probe was inserted into the rectum of the mouse to
45
46 monitor its core temperature of approximately 37°C. Electrode gel was placed on the
47
48 ECG sensors of the heated platform. Parasternal long-axis images inclusive of two-
49
50 dimensional loops and freeze-frame end-diastolic images were collected to measure
51
52 end-diastolic LV cavity dimension (LVID, d), and posterior wall thickness (LVPW, d).
53
54 Parasternal short axis images at the level of papillary muscles using M-mode were
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 also collected to determine LVPW and LVID, in both systole (s) and diastole (d), as
5
6 previously described (34). Parasternal long axis and M mode measurements were
7
8 used to calculate functional parameters including fractional shortening (FS%) and
9
10 ejection fraction (EF%).
11
12
13

14 **Electrocardiogram**

15
16
17
18 Surface electrocardiogram analysis was conducted on mice anesthetized with
19
20 isoflurane (2% in 1L/min oxygen). Anesthesia was maintained by administration of
21
22 oxygen and approximately 1% isoflurane during the whole recording procedure. Mice
23
24 were immobilized on a heated imaging stage during acquisition. Lead II ECGs were
25
26 collected using PowerLab equipment (AD Instruments). Subsurface ECG recordings
27
28 were collected from anesthetized mice around three months of age for a 5-min
29
30 interval of recording. Mice at ~three months of age were stimulated with epinephrine
31
32 (2mg/kg) under isoflurane sedation and ventricular arrhythmic events were calculated
33
34 over a 30-min period. Conscious ECGs were also collected using implanted radio-
35
36 telemetry devices using an ETA-F10 miniature telemeter (DSI) and Dataquest A.R.T
37
38 acquisition software around six months of age for baseline and post stimulation
39
40 measurements. All conscious ECGs were analyzed using LabChart software.
41
42 Researchers blinded to genotype performed data collection and analysis. Conscious
43
44 mice were stimulated with epinephrine (2mg/kg). After a week of rest, mice were
45
46 stimulated with epinephrine (2mg/kg) and caffeine (120mg/kg, Millipore Sigma
47
48 C1778) at the same time. ECG recordings were collected before stimulation to
49
50 measure baseline ECG features. Mice were then recorded for an hour post-
51
52 stimulation. The total number of ventricular arrhythmic events were calculated by
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 combining the number of arrhythmic events such as bigeminy (>10 consecutive
5 abnormal ventricular beats alternating with normal ventricular beats), ventricular
6 tachycardia (>10 consecutive beats of tachycardia), non-sustained ventricular
7 tachycardia (three to ten consecutive beats), and isolated ventricular arrhythmic
8 events such as premature ventricular contractions (PVCs) and ventricular couplets.
9

16 **Immunoblotting**

20 Heart tissue samples were isolated from seven-week and six-month old mice
21 after being euthanized using CO₂ and homogenized using a Cryolys-cooled Precellys
22 24 bead homogenizer (Bertin Corp.) using a combination of 1.4mm and 2.8mm
23 ceramic beads at 6000rpm for three bouts of 15 seconds in homogenization buffer
24 (0.025M Tris-HCl, 0.15M NaCl, 0.001M EDTA, 1% v/v NP-40, 5% v/v glycerol,
25 pH=7.4), as previously described (35). Homogenates were then centrifuged for 30
26 minutes at high speed at 4°C. Following quantification by BCA assay (Pierce), 30-
27 40ug of lysates were separated on 4-15% precast ProteanTGX gels (Bio-Rad) and
28 transferred to nitrocellulose membranes. Membranes were blocked at room
29 temperature for 1 hour and then incubated in primary antibody overnight at 4°C.
30 Primary antibodies targeted Ankyrin-B (1:1000, Covance antibody) (7), Na⁺/Ca²⁺
31 exchanger 1 (NCX1) (1:1000, Cell Signaling Technology CST 79350), NKA (1:1000,
32 Cell Signaling Technology CST 3010), and Ankyrin-G (1:1000, Covance, a gift from
33 Dr. Paul Jenkins) (36). Secondary antibodies used were donkey anti-rabbit or donkey
34 anti-mouse (Jackson ImmunoResearch Laboratories, Bio-Rad). Densitometry
35 analysis was performed using ImageJ software.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

60 **Histologic analysis**

1
2
3
4 Hearts were excised and fixed in 10% neutral buffered formalin for 24 hours and
5
6 then stored in 100% ethanol at 4° C until sectioning. Masson's trichrome staining was
7
8 performed on 5µm sections at the histology core at the Wexner Medical Center at the
9
10 Ohio State University. Trichrome-stained cardiac sections were collected on an
11
12 EVOS microscope (Thermo Scientific). Researchers blinded to genotype performed
13
14 image collection and analysis. Whole-heart images were edited in Adobe Photoshop
15
16 to excise aortic tissue, as the focus of the study is intra-myocardial fibrosis. Fibrosis
17
18 was quantified using an add-on to MATLAB (Mathworks). The add-on converts
19
20 images from the RGB color space into CIELAB color space, then segments images
21
22 using the kmeans algorithm as previously described (35). Finally, the fibrosis (blue)
23
24 segment is filtered through a color mask to remove noise, and the ratio of fibrosis to
25
26 healthy red tissue is calculated.
27
28
29
30
31

32 33 34 **Isolation of cardiomyocytes**

35
36
37 Adult mouse ventricular cardiomyocytes were prepared as previously described
38
39 (37). Murine hearts from male and female mice were obtained after animals were
40
41 euthanized by CO2 asphyxiation followed by cervical dislocation in accordance with
42
43 the Guide for the Care and Use of Laboratory Animals published by the National
44
45 Institutes of Health and the Ohio State University Institutional Animal Care and Use
46
47 Committee-approved protocols. Following isolation, cells were fixed in ethanol and
48
49 stored at -20°C till staining experiments.
50
51
52
53
54

55 **Immunofluorescence**

56
57
58
59
60
61
62
63
64
65

1
2
3
4 Adult ventricular myocytes were isolated, and processed for
5 immunofluorescence as previously described (38). For adult ventricular myocytes,
6 staining experiments were performed in solution. Briefly, cells were blocked for 1 hour
7 in blocking solution (3% fish gel, 0.75% triton-100(10%) and 1% DMSO). Cells were
8 incubated in primary antibodies at 4°C overnight while rotating. Primary antibodies
9 included NCX (Swant R3F1, 1:100), Ankyrin-B (1:100, Covance antibody) (7) and
10 NKA (Abcam ab7671, 1:100). Secondary antibodies, including anti-rabbit and anti-
11 mouse conjugated to Alexa-Fluor, were applied to the samples for 2 hours at room
12 temperature. For control experimental, parallel samples were incubated with
13 secondary antibodies and with primary antibody controls for 2 hours at room
14 temperature and processed to ensure lack of non-specific secondary antibody
15 staining. After secondary antibody incubation for 2 hours, cells were extensively
16 washed, applied to the slides in Vectashield imaging medium (Vector Laboratories,
17 Newark, CA, USA), and then coverslips (#1) were applied. Images were collected on
18 a confocal microscope (LSM 510 Meta, Zeiss, Oberkochen, Germany). Images were
19 collected using identical confocal protocol settings at room temperature, and the
20 observer was blinded to the genotype. Quantification of signal intensity was
21 performed using image J software. Area of overlap between two signals was
22 calculated using ROI (region of interest) manager under Image J software. All
23 calculations were normalized to control.

24 **Detection of cytosolic Ca²⁺ by confocal microscopy**

25 Control or AnkBp.E1458G^{+/+} myocytes were loaded with 10 μM Fluo-4-AM
26 (Thermo Fisher Scientific, MA, United States) for 20 minutes at RT. After 10-20
27

1
2
3
4 minutes of de-esterification in free dye solution, the myocytes were mounted in an
5
6 imaging chamber (Warner Instruments, CT, United States) and continuously
7
8 superfused with an external solution containing (in mM): 137.0 NaCl, 5.4 KCl, 4.5
9
10 MgCl₂, 0.16 NaH₂PO₄, 3 NaHCO₃, 20.0 HEPES, 10.0 glucose, 10.4 taurine, 1.8
11
12 CaCl₂. Intracellular Ca²⁺ transients were induced by electrical field stimulation (SD9
13
14 stimulator, Grass Technologies/Astro-Med Inc., RI, United States). After stabilization
15
16 (usually 3–5 min) imaging was performed using Olympus FluoView FV 1000
17
18 (Olympus America Inc., PA, United States) confocal microscope system equipped
19
20 with x60 oil-immersion objective lens (NA 1.4). Fluo-4 was excited with a 488 nm line
21
22 of argon laser, and the signal was collected at 500–600 nm wavelengths. Line-
23
24 scanning (512 × 512 pixels, 2.0 μS/pixel and 2.1 msec per line) was performed along
25
26 the longitudinal axis of cells (avoiding nuclei). Fluorescence signals were normalized
27
28 to the baseline cellular fluorescence (F₀). Ca²⁺ transients were analyzed as the F/F₀
29
30 mean value over 10-15 transients for each image. In the experiments with
31
32 Isoproterenol (ISO) treatment, the drug was administered to the perfusion buffer.
33
34 Spontaneous Ca²⁺ waves were evaluated during 35 sec after stimulation at 2 Hz.
35
36 Ca²⁺ alternans were induced incrementally by increasing the pacing frequency (1 to
37
38 5 Hz).
39
40
41
42
43
44
45
46
47

48 **Transverse aortic constriction**

49
50
51
52 Mice were anesthetized with 2% isoflurane and intubated for artificial ventilation
53
54 at 120–160 breaths per minute, tidal volume of 0.2–0.35 ml. A Heating pad was used
55
56 to keep body temperatures at 37 °C throughout the procedure. The procedure was
57
58 performed on three-month-old mice as previously described (35). Briefly, the
59
60
61
62
63
64
65

1
2
3
4 transverse aorta was accessed via a left lateral thoracotomy and the aorta was ligated
5
6
7 overlying a blunted 27-gauge needle. The needle was removed immediately following
8
9 ligation leaving a discrete region of stenosis at the aorta. Successful constriction was
10
11 confirmed by checking the aortic root and the constriction site using
12
13 echocardiography. The surgeon was blinded to genotype.
14
15

16 17 **Quantitative real-time PCR**

18
19
20 Real-time PCR was performed as previously described (34). Briefly, total RNA
21
22 from the mouse heart tissues was extracted with TRIzol Reagent (Invitrogen)
23
24 following manufacturer's instructions; 1 µg of total RNA, treated with ezDNase, was
25
26 used for the first-strand complementary DNA synthesis using SuperScript IV Vilo
27
28 Master Mix (Thermo Fisher Scientific). qRT-PCR reactions were performed in
29
30 triplicate in 96-well optical plates with PowerUp SYBR Green Master Mix (Thermo
31
32 Fisher Scientific). Primers for *Ank2*- F: TACAACCAACGTGTCTGCCA and R:
33
34 TGCAAAGGCAACAGACTCCT; *Nppa*- F: 5'-CTGGAAGTGGGAGGTCAAC-3', R: 5'-
35
36 AGGGCAGATCTATCGGAGGG-3'; *Nppb*- F: 5'-GCTCCCAATCCATCACAGA-3',
37
38 R: 5'-CTGCCTTGAGACCGAAGGAC-3'; *Myh7*- F: 5-
39
40 TGACAGAGGAGATGGCTGGT-3', R: 5'-CCTTGGCCTTGGTCAGAGTA-3';
41
42 *Col1a1*- F: 5'-TCCTTCCTCTACACAGGGTCC-3', R: 5'-
43
44 CGGCCACCATCTTGAGACTT-3'; *Timp1*- F: 5'-GGCATCTGGCATCCTCTTGT-3',
45
46 R: 5'-CAGGTCCGAGTTGCAGAAGG-3'. *Hprt* levels were used as a normalization
47
48 control.
49
50
51
52
53
54
55

56 57 **Fast Fourier Transformation (FFT) Analysis**

1
2
3
4 Heart rate variability was measured via fast Fourier transformation (FFT) based
5
6 time- and frequency-domain analysis. Custom MATLAB script (39) allowed FFT
7
8 analysis of text files with every raw RR interval within a period of time. To prepare
9
10 data for MATLAB analysis, ECG recordings were edited on Lab chart, and all noise
11
12 was removed. Each RR interval was then measured by Lab chart and exported into
13
14 a text file in 2-minute increments to screen for potential noise missed in the initial edit.
15
16 A total of 14 minutes was analyzed for RR and SDRR intervals and also FFT analyzed
17
18 to determine low-frequency (LF) and high-frequency (HF) spectra, LF/HF, etc. (LF
19
20 range 0.15-1.5 Hz, HF range 1.5-5 Hz).
21
22
23
24
25

26 **Immunoprecipitation**

27
28
29 Control and AnkBp.E1458G^{+/+} mouse heart samples were homogenized in
30
31 buffer (containing 0.025 m Tris-HCl, 0.15 m NaCl, 0.001 m EDTA, 1% (v/v) Nonidet
32
33 P-40, 5% (v/v) glycerol, pH 7.4) using the bead homogenizer. Lysates were
34
35 centrifuged for 30 min at 13,000 rpm at 4 °C. 400µg of supernatant was incubated
36
37 and rotated with AnkB-Ig (Covance, custom-made antibody) or control IgG at 4 °C
38
39 overnight. Following incubation, lysates with antibodies were rotated and incubated
40
41 with Protein A/G Magnetic Beads (Pierce, number 88802) for 4-5 h at 4 °C. The
42
43 supernatant was then removed from the beads using a magnetic stand, and the
44
45 beads were washed 3 times with PBS containing 500mM NaCl. Bound protein was
46
47 eluted with 2× Laemmli sample buffer and β-mercaptoethanol and heated to 95 °C
48
49 for 10 min before immunoblotting with NKA (1:750, Cell Signaling Technology CST
50
51 3010).
52
53
54
55
56
57
58

59 **Statistics**

1
2
3
4 Data are presented as mean \pm SEM. For the comparison of two groups, we
5
6 performed unpaired two-tailed student t-test when data passed normality test
7
8 (Shapiro-Wilk normality test). When data did not pass Shapiro-Wilk normality test, we
9
10 performed Mann-Whitney U test (non-parametric for unpaired comparison) to
11
12 compare two groups. For comparison of more than 2 groups, ANOVA test was
13
14 performed when data passed Shapiro-Wilk normality test followed by Tukey's
15
16 multiple comparisons test. When data did not pass Shapiro-Wilk normality test,
17
18 Kruskal-Wallis test (non-parametric) was performed followed by Dunn's multiple
19
20 comparisons test. For cardiac function parameters (EF, FS, LVIDd, LVIDs) measured
21
22 over time in response to TAC, data was screened graphically with model residuals,
23
24 homoskedasticity, and QQ plots to ensure the applicability of a two-way ANOVA. A
25
26 two-way ANOVA mixed effects model for repeated measures was then used with
27
28 post-hoc Holm-Šídák multiple comparisons test. Sphericity was not assumed, and
29
30 the Geisser-Greenhouse correction was deployed. For our study, a value of $p < 0.05$
31
32 was considered statistically significant.
33
34
35
36
37
38
39
40

41 **Data availability**

42
43
44
45 All data are available within the manuscript or supporting information.
46
47

48 **Supporting information**

49
50
51
52 This article contains supporting information.
53
54

55 **Acknowledgements**

1
2
3
4 The authors would like to acknowledge the University of Michigan Transgenic Animal
5
6 Model Core for their help in the generation of the AnkBp.E1458G murine model. The
7
8 authors would also like to acknowledge the Ohio State University College of
9
10 Veterinary Medicine Comparative Pathology & Digital Imaging Shared Resource for
11
12 their assistance with histology services.
13
14

15 16 17 **Funding**

18
19
20 The authors are supported by NIH grants, HL146969 to M.E.R., HL135754 to P.J.M.,
21
22 HL156652 to T.J.H., HL063043, HL074045 to S.G., a grant from the Ohio State Frick
23
24 Center for Heart Failure and Arrhythmia and the Leducq Foundation (TNE FANTASY
25
26 19CV03) to P.J.M. and M.E.M. The content is solely the responsibility of the authors
27
28 and does not necessarily represent the official views of the National Institutes of
29
30 Health.
31
32
33

34 35 36 **Conflict of Interest**

37
38
39 The authors declare that they have no conflicts of interest with the contents of this
40
41 article.
42
43

44 45 46 **Author contributions**

47
48 M.E.R. and P.J.M. conceived and designed the project; M.E.R., M.J.W., J.I.M. , M.H.,
49
50 L.J.Y., T.L.S., S.A-B., N.M., D.A., O.C., S.S.T., N.P.M. and X.X. performed
51
52 experiments; M.E.R., M.J.W., J.I.M., O.C., S.S.T., L.J.Y., S.A.-B. analyzed data;
53
54 M.E.R, M.J.W., J.I.M., T.L.S., J.D.R, T.J.H., M.E.M., S.G. and P.J.M. interpreted the
55
56 results of experiments; M.E.R., J.I.M. and M.J.W. prepared figures; M.E.R., M.J.W.,
57
58
59
60
61
62
63
64
65

1
2
3
4 J.I.M., J.D.R., S.G. and P.J.M. drafted the manuscript. All authors have contributed
5
6 and agreed to the final version of the manuscript.
7
8
9

10 **References**

- 11
12
13 1. Scotland, P., Zhou, D., Benveniste, H., and Bennett, V. (1998) Nervous
14 system defects of AnkyrinB (-/-) mice suggest functional overlap between the
15 cell adhesion molecule L1 and 440-kD AnkyrinB in premyelinated axons. *J*
16 *Cell Biol* **143**, 1305-1315
17
18
- 19 2. Cunha, S. R., Bhasin, N., and Mohler, P. J. (2007) Targeting and stability of
20 Na/Ca exchanger 1 in cardiomyocytes requires direct interaction with the
21 membrane adaptor ankyrin-B. *J Biol Chem* **282**, 4875-4883
22
23
- 24 3. Koenig, S. N., and Mohler, P. J. (2017) The evolving role of ankyrin-B in
25 cardiovascular disease. *Heart Rhythm* **14**, 1884-1889
26
27
- 28 4. Cunha, S. R., Le Scouarnec, S., Schott, J. J., and Mohler, P. J. (2008) Exon
29 organization and novel alternative splicing of the human ANK2 gene:
30 implications for cardiac function and human cardiac disease. *J Mol Cell Cardiol*
31 **45**, 724-734
32
33
- 34 5. Lopes, L. R., Syrris, P., Guttman, O. P., O'Mahony, C., Tang, H. C.,
35 Dalageorgou, C., Jenkins, S., Hubank, M., Monserrat, L., McKenna, W. J.,
36 Plagnol, V., and Elliott, P. M. (2015) Novel genotype-phenotype associations
37 demonstrated by high-throughput sequencing in patients with hypertrophic
38 cardiomyopathy. *Heart* **101**, 294-301
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
6. Curran, J., and Mohler, P. J. (2011) Coordinating electrical activity of the heart: ankyrin polypeptides in human cardiac disease. *Expert Opin Ther Targets* **15**, 789-801
 7. Roberts, J. D., Murphy, N. P., Hamilton, R. M., Lubbers, E. R., James, C. A., Kline, C. F., Gollob, M. H., Krahn, A. D., Sturm, A. C., Musa, H., El-Refaey, M., Koenig, S., Aneq, M. A., Hoorntje, E. T., Graw, S. L., Davies, R. W., Rafiq, M. A., Koopmann, T. T., Aafaqi, S., Fatah, M., Chiasson, D. A., Taylor, M. R., Simmons, S. L., Han, M., van Opbergen, C. J., Wold, L. E., Sinagra, G., Mittal, K., Tichnell, C., Murray, B., Codima, A., Nazer, B., Nguyen, D. T., Marcus, F. I., Sobriera, N., Lodder, E. M., van den Berg, M. P., Spears, D. A., Robinson, J. F., Ursell, P. C., Green, A. K., Skanes, A. C., Tang, A. S., Gardner, M. J., Hegele, R. A., van Veen, T. A., Wilde, A. A., Healey, J. S., Janssen, P. M., Mestroni, L., van Tintelen, J. P., Calkins, H., Judge, D. P., Hund, T. J., Scheinman, M. M., and Mohler, P. J. (2019) Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. *J Clin Invest* **129**, 3171-3184
 8. Choi, C. S. W., Souza, I. A., Sanchez-Arias, J. C., Zamponi, G. W., Arbour, L. T., and Swayne, L. A. (2019) Ankyrin B and Ankyrin B variants differentially modulate intracellular and surface Cav2.1 levels. *Mol Brain* **12**, 75
 9. Lin, Y., Williams, N., Wang, D., Coetzee, W., Zhou, B., Eng, L. S., Um, S. Y., Bao, R., Devinsky, O., McDonald, T. V., Sampson, B. A., and Tang, Y. (2017) Applying High-Resolution Variant Classification to Cardiac Arrhythmogenic

1
2
3
4 Gene Testing in a Demographically Diverse Cohort of Sudden Unexplained
5 Deaths. *Circ Cardiovasc Genet* **10**
6
7

- 8
9
10 10. Hedley, P. L., Jorgensen, P., Schlamowitz, S., Wangari, R., Moolman-Smook,
11 J., Brink, P. A., Kanters, J. K., Corfield, V. A., and Christiansen, M. (2009) The
12 genetic basis of long QT and short QT syndromes: a mutation update. *Hum*
13 *Mutat* **30**, 1486-1511
14
15
16
17
18 11. Mitchell, G. F., Jeron, A., and Koren, G. (1998) Measurement of heart rate and
19 Q-T interval in the conscious mouse. *Am J Physiol* **274**, H747-751
20
21
22
23 12. Mulla, W., Murninkas, M., Levi, O., and Etzion, Y. (2022) Incorrectly corrected?
24 QT interval analysis in rats and mice. *Front Physiol* **13**, 1002203
25
26
27
28 13. Roussel, J., Champeroux, P., Roy, J., Richard, S., Fauconnier, J., Le
29 Guennec, J. Y., and Thireau, J. (2016) The Complex QT/RR Relationship in
30 Mice. *Sci Rep* **6**, 25388
31
32
33
34
35 14. Kmecova, J., and Klimas, J. (2010) Heart rate correction of the QT duration in
36 rats. *Eur J Pharmacol* **641**, 187-192
37
38
39
40 15. Billman, G. E. (2013) The LF/HF ratio does not accurately measure cardiac
41 sympatho-vagal balance. *Front Physiol* **4**, 26
42
43
44
45 16. Laurita, K. R., and Rosenbaum, D. S. (2008) Cellular mechanisms of
46 arrhythmogenic cardiac alternans. *Prog Biophys Mol Biol* **97**, 332-347
47
48
49
50 17. Florea, S. M., and Blatter, L. A. (2012) Regulation of cardiac alternans by beta-
51 adrenergic signaling pathways. *Am J Physiol Heart Circ Physiol* **303**, H1047-
52 1056
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 18. Hammer, K. P., Ljubojevic, S., Ripplinger, C. M., Pieske, B. M., and Bers, D.
5
6 M. (2015) Cardiac myocyte alternans in intact heart: Influence of cell-cell
7
8 coupling and beta-adrenergic stimulation. *J Mol Cell Cardiol* **84**, 1-9
9
10
11 19. Le Scouarnec, S., Bhasin, N., Vieyres, C., Hund, T. J., Cunha, S. R., Koval,
12
13 O., Marionneau, C., Chen, B., Wu, Y., Demolombe, S., Song, L. S., Le Marec,
14
15 H., Probst, V., Schott, J. J., Anderson, M. E., and Mohler, P. J. (2008)
16
17 Dysfunction in ankyrin-B-dependent ion channel and transporter targeting
18
19 causes human sinus node disease. *Proc Natl Acad Sci U S A* **105**, 15617-
20
21 15622
22
23
24
25 20. Hertz, C. L., Christiansen, S. L., Larsen, M. K., Dahl, M., Ferrero-Miliani, L.,
26
27 Weeke, P. E., Pedersen, O., Hansen, T., Grarup, N., Ottesen, G. L., Frank-
28
29 Hansen, R., Banner, J., and Morling, N. (2016) Genetic investigations of
30
31 sudden unexpected deaths in infancy using next-generation sequencing of
32
33 100 genes associated with cardiac diseases. *Eur J Hum Genet* **24**, 817-822
34
35
36
37 21. Neubauer, J., Lecca, M. R., Russo, G., Bartsch, C., Medeiros-Domingo, A.,
38
39 Berger, W., and Haas, C. (2017) Post-mortem whole-exome analysis in a large
40
41 sudden infant death syndrome cohort with a focus on cardiovascular and
42
43 metabolic genetic diseases. *Eur J Hum Genet* **25**, 404-409
44
45
46
47 22. Reuter, M. S., Walker, S., Thiruvahindrapuram, B., Whitney, J., Cohn, I.,
48
49 Sondheimer, N., Yuen, R. K. C., Trost, B., Paton, T. A., Pereira, S. L., Herbrick,
50
51 J. A., Wintle, R. F., Merico, D., Howe, J., MacDonald, J. R., Lu, C.,
52
53 Nalpathamkalam, T., Sung, W. W. L., Wang, Z., Patel, R. V., Pellicchia, G.,
54
55 Wei, J., Strug, L. J., Bell, S., Kellam, B., Mahtani, M. M., Bassett, A. S.,
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Bombard, Y., Weksberg, R., Shuman, C., Cohn, R. D., Stavropoulos, D. J.,
5
6 Bowdin, S., Hildebrandt, M. R., Wei, W., Romm, A., Pasceri, P., Ellis, J., Ray,
7
8 P., Meyn, M. S., Monfared, N., Hosseini, S. M., Joseph-George, A. M., Keeley,
9
10 F. W., Cook, R. A., Fiume, M., Lee, H. C., Marshall, C. R., Davies, J., Hazell,
11
12 A., Buchanan, J. A., Szego, M. J., and Scherer, S. W. (2018) The Personal
13
14 Genome Project Canada: findings from whole genome sequences of the
15
16 inaugural 56 participants. *CMAJ* **190**, E126-E136
17
18
19
20

21 23. Ware, J. S., Walsh, R., Cunningham, F., Birney, E., and Cook, S. A. (2012)
22
23 Paralogous annotation of disease-causing variants in long QT syndrome
24
25 genes. *Hum Mutat* **33**, 1188-1191
26
27

28 24. Adler, A., Novelli, V., Amin, A. S., Abiusi, E., Care, M., Nannenber, E. A.,
29
30 Feilotter, H., Amenta, S., Mazza, D., Bikker, H., Sturm, A. C., Garcia, J.,
31
32 Ackerman, M. J., Hershberger, R. E., Perez, M. V., Zareba, W., Ware, J. S.,
33
34 Wilde, A. A. M., and Gollob, M. H. (2020) An International, Multicentered,
35
36 Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long
37
38 QT Syndrome. *Circulation* **141**, 418-428
39
40
41
42

43 25. Giudicessi, J. R., and Ackerman, M. J. (2020) Established Loss-of-Function
44
45 Variants in ANK2-Encoded Ankyrin-B Rarely Cause a Concerning Cardiac
46
47 Phenotype in Humans. *Circ Genom Precis Med* **13**, e002851
48
49

50 26. Sosnowski, M., and Petelenz, T. (1995) Heart rate variability. Is it influenced
51
52 by disturbed sinoatrial node function? *J Electrocardiol* **28**, 245-251
53
54

55 27. Cruz, F. M., Sanz-Rosa, D., Roche-Molina, M., Garcia-Prieto, J., Garcia-Ruiz,
56
57 J. M., Pizarro, G., Jimenez-Borreguero, L. J., Torres, M., Bernad, A., Ruiz-
58
59
60
61

1
2
3
4 Cabello, J., Fuster, V., Ibanez, B., and Bernal, J. A. (2015) Exercise triggers
5 ARVC phenotype in mice expressing a disease-causing mutated version of
6 human plakophilin-2. *J Am Coll Cardiol* **65**, 1438-1450
7
8

9
10
11 28. Stevens, T. L., Wallace, M. J., Refaey, M. E., Roberts, J. D., Koenig, S. N.,
12 and Mohler, P. J. (2020) Arrhythmogenic Cardiomyopathy: Molecular Insights
13 for Improved Therapeutic Design. *J Cardiovasc Dev Dis* **7**
14
15

16
17
18 29. Inserte, J., Garcia-Dorado, D., Hernando, V., and Soler-Soler, J. (2005)
19 Calpain-mediated impairment of Na⁺/K⁺-ATPase activity during early
20 reperfusion contributes to cell death after myocardial ischemia. *Circ Res* **97**,
21 465-473
22
23

24
25
26 30. Skogestad, J., Aronsen, J. M., Tovsrud, N., Wanichawan, P., Hougen, K.,
27 Stokke, M. K., Carlson, C. R., Sjaastad, I., Sejersted, O. M., and Swift, F.
28 (2020) Coupling of the Na⁺/K⁺-ATPase to Ankyrin B controls Na⁺/Ca²⁺
29 exchanger activity in cardiomyocytes. *Cardiovasc Res* **116**, 78-90
30
31

32
33
34 31. Li, Q., Pogwizd, S. M., Prabhu, S. D., and Zhou, L. (2014) Inhibiting Na⁺/K⁺
35 ATPase can impair mitochondrial energetics and induce abnormal Ca²⁺
36 cycling and automaticity in guinea pig cardiomyocytes. *PLoS One* **9**, e93928
37
38

39
40
41 32. Landstrom, A. P., Dobrev, D., and Wehrens, X. H. T. (2017) Calcium Signaling
42 and Cardiac Arrhythmias. *Circ Res* **120**, 1969-1993
43
44

45
46
47 33. Cerrone, M., Montnach, J., Lin, X., Zhao, Y. T., Zhang, M., Agullo-Pascual, E.,
48 Leo-Macias, A., Alvarado, F. J., Dolgalev, I., Karathanos, T. V., Malkani, K.,
49 Van Opbergen, C. J. M., van Bavel, J. J. A., Yang, H. Q., Vasquez, C., Tester,
50 D., Fowler, S., Liang, F., Rothenberg, E., Heguy, A., Morley, G. E., Coetzee,
51
52
53
54
55
56
57
58
59
60
61

1
2
3
4 W. A., Trayanova, N. A., Ackerman, M. J., van Veen, T. A. B., Valdivia, H. H.,
5
6 and Delmar, M. (2017) Plakophilin-2 is required for transcription of genes that
7
8 control calcium cycling and cardiac rhythm. *Nat Commun* **8**, 106
9

10
11 34. Cavus, O., Williams, J., Musa, H., El Refaey, M., Gratz, D., Shaheen, R.,
12
13 Schwieterman, N. A., Koenig, S., Antwi-Boasiako, S., Young, L. J., Xu, X.,
14
15 Han, M., Wold, L. E., Hund, T. J., Mohler, P. J., and Bradley, E. A. (2021) Giant
16
17 ankyrin-G regulates cardiac function. *J Biol Chem* **296**, 100507
18
19

20
21 35. Lubbers, E. R., Murphy, N. P., Musa, H., Huang, C. Y., Gupta, R., Price, M.
22
23 V., Han, M., Daoud, E., Gratz, D., El Refaey, M., Xu, X., Hoeflinger, N. K.,
24
25 Friel, E. L., Lancione, P., Wallace, M. J., Cavus, O., Simmons, S. L., Williams,
26
27 J. L., Skaf, M., Koenig, S. N., Janssen, P. M. L., Rasband, M. N., Hund, T. J.,
28
29 and Mohler, P. J. (2019) Defining new mechanistic roles for alphaII spectrin in
30
31 cardiac function. *J Biol Chem* **294**, 9576-9591
32
33

34
35 36. Jenkins, P. M., Kim, N., Jones, S. L., Tseng, W. C., Svitkina, T. M., Yin, H. H.,
36
37 and Bennett, V. (2015) Giant ankyrin-G: a critical innovation in vertebrate
38
39 evolution of fast and integrated neuronal signaling. *Proc Natl Acad Sci U S A*
40
41 **112**, 957-964
42
43

44
45 37. Koval, O. M., Snyder, J. S., Wolf, R. M., Pavlovicz, R. E., Glynn, P., Curran,
46
47 J., Leymaster, N. D., Dun, W., Wright, P. J., Cardona, N., Qian, L., Mitchell, C.
48
49 C., Boyden, P. A., Binkley, P. F., Li, C., Anderson, M. E., Mohler, P. J., and
50
51 Hund, T. J. (2012) Ca²⁺/calmodulin-dependent protein kinase II-based
52
53 regulation of voltage-gated Na⁺ channel in cardiac disease. *Circulation* **126**,
54
55 2084-2094
56
57
58
59
60
61

- 1
2
3
4 38. El Refaey, M., Coles, S., Musa, H., Stevens, T. L., Wallace, M. J., Murphy, N.
5
6 P., Antwi-Boasiako, S., Young, L. J., Manring, H. R., Curran, J., Makara, M.
7
8 A., Sas, K., Han, M., Koenig, S. N., Skaf, M., Kline, C. F., Janssen, P. M. L.,
9
10 Accornero, F., Borzok, M. A., and Mohler, P. J. (2022) Altered Expression of
11
12 Zonula occludens-1 Affects Cardiac Na(+) Channels and Increases
13
14 Susceptibility to Ventricular Arrhythmias. *Cells* **11**
15
16
17
18
19 39. Bidaud, I., D'Souza, A., Forte, G., Torre, E., Greuet, D., Thirard, S., Anderson,
20
21 C., Chung You Chong, A., Torrente, A. G., Roussel, J., Wickman, K., Boyett,
22
23 M. R., Mangoni, M. E., and Mesirca, P. (2020) Genetic Ablation of G Protein-
24
25 Gated Inwardly Rectifying K(+) Channels Prevents Training-Induced Sinus
26
27 Bradycardia. *Front Physiol* **11**, 519382
28
29
30

31 **Figure legends**

32
33
34
35 **Figure 1. Creation of a novel AnkBp.E1458G knock-in mouse model. A.**
36
37 Diagrammatic illustration denoting the location of the variant in the spectrin-binding
38
39 domain of canonical ankyrin-B. **B-C** Representative Sanger sequencing
40
41 chromatogram denoting the amino acid sequence in the control and the
42
43 AnkBp.E1458G^{+/+} mice and confirming the substitution of the Glutamic acid (E) by
44
45 Glycine (G) **D.** *Ank2* relative expression in control and AnkBp.E1458G^{+/+} mice at
46
47 seven weeks of age (N=4 mice/genotype), data passed Shapiro-Wilk normality test
48
49 and unpaired t-test was performed. **E-F.** Immunoblotting and quantitative analysis of
50
51 normalized AnkB expression in the control and the AnkBp.E1458G^{+/+} mice (N=4
52
53 mice/genotype), data passed Shapiro-Wilk normality test and unpaired t-test was
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 performed. Red arrow denotes the change in the amino acid. Yellow arrows denote
5
6 the multiple silent coding changes to block the Cas9 targets.
7
8

9
10 **Figure 2. AnkBp.E1458G^{+/+} mice display a cardiac phenotype at ~six months of**

11 **age. A.** Control and AnkBp.E1458G^{+/+} mice do not display changes in the ejection
12 fraction around three months of age (young mice), data passed Shapiro-Wilk
13 normality test and unpaired t-test was performed. **B-D.** Quantitative analysis and
14 representative echocardiographs denoting a reduction in ejection fraction in the
15 AnkBp.E1458G^{+/+} vs. the control littermates at ~six months of age (Con, N=7 and
16 AnkBp.E1458G^{+/+}, N=11) Scale bars equal 2mm. Data passed Shapiro-Wilk
17 normality test and unpaired t-test was performed. **E.** H&E staining and **F.** Masson
18 Trichrome staining using control and AnkBp.E1458G^{+/+} heart sections in aged mice
19 (Con, N=4 and AnkBp.E1458G^{+/+}, N=5). **G.** Heart weight relative to tibial length in the
20 two groups of mice (Con, N=6 and AnkBp.E1458G^{+/+}, N=7, around five months of
21 age). Data passed Shapiro-Wilk normality test and unpaired t-test was performed. **H.**
22 Quantitative analysis of fibrosis (Con, N=4 and AnkBp.E1458G^{+/+}, N=5, around five
23 months of age). Scale bars equal 1mm. Data passed Shapiro-Wilk normality test and
24 unpaired t-test was performed.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 **Figure 3. Aged AnkBp.E1458G^{+/+} mice display electrical dysfunction at rest. A.**

48 Average heart rate, **B.** Maximal heart rate, **C.** P wave duration, **D.** PR interval, **E.**
49 QRS interval, **F.** RR interval, **G.** QT interval and **H.** QTc (Mitchell) using radio-
50 implanted telemeters in control and AnkBp.E1458G^{+/+} mice around six months of age
51 (Con, N=7 and AnkBp.E1458G, N=10). Data passed Shapiro-Wilk normality tests and
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 unpaired t-tests were performed (A-G). Data did not pass Shapiro-Wilk normality test
5
6 and non-parametric (Mann-Whitney test) was performed.
7
8

9
10 **Figure 4. Aged AnkBp.E1458G^{+/+} mice display heart rate variability at rest. A.**

11 High frequency (HF) and **B.** Low frequency (LF) spectral components of heart rate
12 variability HRV. Data did not pass Shapiro-Wilk normality tests and non-parametric
13 (Mann-Whitney tests) were performed. **C.** LF/HF using Fast Fourier transform (FFT)
14 analysis and radio-implanted telemeters in control and AnkBp.E1458G^{+/+} mice
15 around six months of age (Con, N=13 and AnkBp.E1458G^{+/+}, N=16). Data passed
16 Shapiro-Wilk normality test and unpaired t-test was performed. **D.** RR-Interval, data
17 passed Shapiro-Wilk normality test and unpaired t-test was performed. **E.** SDRR-
18 Interval, data did not pass Shapiro-Wilk normality test and non-parametric (Mann-
19 Whitney test) was performed. **F.** representative traced from control and
20 AnkBp.E1458G^{+/+} mice over 1 min interval.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **Figure 5. AnkBp.E1458G^{+/+} mice display arrhythmias following adrenergic**

38 **stimulation/stress. A.** AnkBp.E1458G^{+/+} mice display ventricular arrhythmic events
39 after epinephrine stimulation at an early age (~three months of age) under isoflurane
40 sedation (Con, N=6 and AnkBp.E1458G^{+/+}, N=6). Data did not pass Shapiro-Wilk
41 normality test and non-parametric (Mann-Whitney test) was performed. **B-D.**
42 Representative ECG traces denoting PVCs and chain of couplets in the
43 AnkBp.E1458G^{+/+} mice at early age after epinephrine stimulation and under
44 isoflurane sedation.
45
46
47
48
49
50
51
52
53
54
55
56

57 **Figure 6. AnkBp.E1458G^{+/+} mice display a significant pattern of arrhythmia after**

58 **epinephrine and caffeine stimulation. A.** AnkBp.E1458G^{+/+} mice show more
59
60
61
62
63
64
65

1
2
3
4 ventricular arrhythmic events after epinephrine stimulation using implanted
5
6 telemeters around six months of age (Con, N=15 and AnkBp.E1458G^{+/+}, N=22). Data
7
8 did not pass Shapiro-Wilk normality test and non-parametric (Mann-Whitney test)
9
10 was performed. **B.** AnkBp.E1458G^{+/+} mice display significant increase in the number
11
12 of ventricular arrhythmic events after epinephrine and caffeine stimulation using
13
14 telemeters around six months of age (Con, N=6 and AnkBp.E1458G^{+/+}, N=6). **C.**
15
16 AnkBp.E1458G^{+/+} mice exhibit an increase in the number of sustained arrhythmic
17
18 events after epinephrine and caffeine stimulation (Con, N=6 and AnkBp.E1458G^{+/+},
19
20 N=6). Data passed Shapiro-Wilk normality tests and unpaired t-tests were performed
21
22 (B-C). **D.** AnkBp.E1458G^{+/+} mice display longer episodes of the sustained events
23
24 after epinephrine and caffeine stimulation (Con, N=6 and AnkBp.E1458G^{+/+}, N=6).
25
26 Data did not pass Shapiro-Wilk normality test and non-parametric (Mann-Whitney
27
28 test) was performed. **E.** AnkBp.E1458G^{+/+} mice demonstrate a higher number of non-
29
30 sustained ventricular events (NSVT) after epinephrine and caffeine stimulation (Con,
31
32 N=6 and AnkBp.E1458G^{+/+}, N=6). Data did not pass Shapiro-Wilk normality test and
33
34 non-parametric (Mann-Whitney test) was performed. **F-H.** Representative ECG
35
36 traces denoting non-sustained and sustained arrhythmic events in the
37
38 AnkBp.E1458G^{+/+} mice after epinephrine and caffeine stimulation.
39
40
41
42
43
44
45
46
47

48
49 **Figure 7. Calcium handling in AnkBp.E1458G^{+/+} myocytes. A.** Representative
50
51 confocal line-scan images and Ca²⁺ transient profiles recorded in mouse ventricular
52
53 myocytes loaded with Fluo-4-AM and stimulated at 1 Hz, with or without 500 nM ISO
54
55 treatment in control (upper panel) and AnkBp.E1458G^{+/+} (lower panel) myocytes. **B.**
56
57 Summary data on Ca²⁺ transient amplitude and **C.** time constant of single exponential
58
59
60
61
62
63
64
65

1
2
3
4 decay (Tau) in control and AnkBp.E1458G^{+/+} myocytes with or without ISO treatment
5
6 at indicated doses. All groups were compared using paired mixed-effects ANOVA
7
8 followed by Tukey correction. P<0.05 vs control or AnkBp.E1458G^{+/+} without
9
10 treatment was considered significant. N=5-7 animals per group (n=15-34 myocytes).
11
12 Shapiro-Wilk test was used to evaluate normal distribution. **D.** Representative
13
14 confocal line-scan images of control (upper panel) and AnkBp.E1458G^{+/+} myocytes
15
16 (lower panel) showing spontaneous Ca²⁺ waves in 35 seconds post-stimulation at 2
17
18 Hz. **E.** Comparison of the fraction of myocytes with spontaneous Ca²⁺ waves in 35
19
20 seconds post-stimulation at 2 Hz in control and AnkBp.E1458G^{+/+} mice with and
21
22 without ISO treatment. The presence or absence of spontaneous Ca²⁺ waves was
23
24 analyzed using a two-tailed Chi-squared test. N=5-7 animals per group (n=12-36
25
26 myocytes). **F.** Representative confocal line-scan images of control (upper panel) and
27
28 AnkBp.E1458G^{+/+} myocytes stimulated at 3 Hz, showing the presence of alternans
29
30 (lower panel). **G.** Summary data on the fraction of myocytes presenting alternans at
31
32 3 Hz or 4 Hz pacing frequency in control and AnkBp.E1458G^{+/+} myocytes with or
33
34 without ISO treatment. The presence or absence of alternans was analyzed using a
35
36 two-tailed Chi-squared test. P<0.05 vs control in the same condition was considered
37
38 significant. N=4-5 animals per group (n=10-28 myocytes). **H.** Threshold frequency for
39
40 the development of alternans. Only myocytes that manifested alternans between 1-5
41
42 Hz were considered for this analysis. Control and AnkBp.E1458G^{+/+} in each condition
43
44 were compared by student's t-test. P<0.05 vs control in the same condition was
45
46 considered significant. N=4-5 animals per group (n=7-14 myocytes).
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


1
2
3
4 **Figure 8. AnkBp.E1458G^{+/+} mice display severe structural phenotype following**
5 **pressure overload. A.** AnkBp.E1458G^{+/+} mice display a reduction in the ejection
6 fraction at eight and twelve weeks compared to control littermates post TAC surgery
7 (Con and AnkBp.E1458G^{+/+}, N=5-6). Repeated measures two-way ANOVA mixed
8 effects model was performed (time effect: p<0.0001, F=69.98, genotype effect:
9 p<0.05, F=6.52, time-genotype interaction effect: p<0.01, F=3.45) with Holm-Šídák
10 multiple comparisons test represented in figure. **B.** AnkBp.E1458G^{+/+} mice display a
11 reduction in fractional shortening at eight and twelve weeks compared to control
12 littermates post TAC surgery (Con and AnkBp.E1458G^{+/+}, N=5-6). Repeated
13 measures two-way ANOVA mixed effects model was performed (time effect:
14 p<0.0001, F=73.01, genotype effect: p<0.05, F=5.74, time-genotype interaction
15 effect: p<0.01, F=3.23) with Holm-Šídák multiple comparisons test represented in
16 figure. **C-D.** AnkBp.E1458G^{+/+} mice do not display significant changes in left
17 ventricular internal diameter (LVID) during systole and diastole post TAC surgery
18 compared to control littermates. Repeated measures two-way ANOVA mixed effects
19 model was performed ((**C**) LVIDd, time effect: p<0.0001, F=12.04, genotype effect:
20 p<0.05, F=6.94, time-genotype interaction effect: p=0.66, F=0.68, (**D**) LVIDs, time
21 effect: p<0.0001, F=27.28, genotype effect: p<0.05, F=7.37, time-genotype
22 interaction effect: p=0.22, F=1.44) with Holm-Šídák multiple comparisons test
23 represented in figure. **E-G.** Masson trichrome staining and quantitative analysis in the
24 AnkBp.E1458G^{+/+} mice 12-weeks post TAC surgery (Con and AnkBp.E1458G^{+/+},
25 N=5). Data passed Shapiro-Wilk normality test and unpaired t-test was performed.
26 Scale bars equal 1mm. **H.** HW/TL relative to control post TAC (Con, N=3 and
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


1
2
3
4 AnkBp.E1458G^{+/+}, N=5). Data passed Shapiro-Wilk normality test and unpaired t-test
5
6
7 was performed. Mice were around three months at baseline before the surgery.
8
9


10 **Figure 9. Expression of ankyrin-B and ankyrin-binding partners in the**
11 **AnkBp.E1458G^{+/+} heart lysates of aged mice. A-B.** Immunoblotting and
12 quantitative analysis of AnkB normalized to GAPDH illustrating no changes in the
13
14 AnkBp.E1458G^{+/+} hearts. **C-D.** Immunoblotting and quantitative analysis of Na⁺/Ca²⁺
15 exchanger (NCX) normalized to GAPDH showing no changes in the
16
17 AnkBp.E1458G^{+/+} hearts. **E-F.** Immunoblotting and quantitative analysis of Na⁺, K⁺-
18 ATPase (NKA) normalized to GAPDH illustrating a significant reduction in the
19
20 AnkBp.E1458G^{+/+} hearts around six months of age. **G.** No significant changes in the
21
22 expression of AnkG normalized to GAPDH in the AnkBp.E1458G^{+/+} hearts (Con and
23
24 AnkBp.E1458G^{+/+}, N=4). All data passed Shapiro-Wilk normality tests and unpaired
25
26 t-tests were performed.
27
28
29
30
31
32
33
34
35
36


37 **Figure 10. Expression and localization of AnkB and AnkB membrane partners**
38 **in the control and AnkBp.E1458G^{+/+} ventricular myocytes. A.** Na⁺, K⁺-ATPase
39 (NKA) is localized similarly in the ventricular myocytes isolated from the
40
41 AnkBp.E1458G^{+/+} hearts and control hearts at ~2-3 months of age (Con, N=3; n=23
42
43 and AnkBp.E1458G^{+/+}, N=3; n=21). **B.** Sodium calcium exchanger (NCX) is localized
44
45 similarly in the AnkBp.E1458G^{+/+} and control ventricular myocytes at ~2-3 months of
46
47 age (Con, N=3; n=17 and AnkBp.E1458G^{+/+}, N=3; n=20). **C.** NKA localization is
48
49 diminished in AnkBp.E1458G^{+/+} ventricular myocytes in reference to AnkB at ~6
50
51 months of age (Con, N=4; n=29 and AnkBp.E1458G^{+/+}, N=5; n=36). **D.** NCX
52
53 localization remains similar at ~6 months of age in AnkBp.E1458G^{+/+} and control
54
55
56
57
58
59
60
61
62
63
64
65


1
2
3
4 ventricular myocytes (Con, N=5; n=41 and AnkBp.E1458G^{+/+}, N=5; n=38).
5
6 Quantitative analysis of immunofluorescence density overlap normalized to control
7
8 (E) NKA in reference to AnkB and (F) NCX in reference to AnkB in ~2-3 months-of-
9
10 age mice. Quantitative analysis of immunofluorescence density overlap normalized
11
12 to control (G) NKA in reference to AnkB and (H) NCX in reference to AnkB in ~6
13
14 months-of-age mice. Data passed Shapiro-Wilk normality tests and unpaired t-tests
15
16 were performed (E, F and H). Data did not pass Shapiro-Wilk normality tests and
17
18 non-parametric (Mann-Whitney test) was performed (G). Scale bars equal 20µm.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65





























[Click here to access/download](#)

Supporting Information (For Publication)

Supporting Informan April 10 No track changes.docx



Michael J. Wallace: Methodology, Software, Validation, Formal analysis, Investigation, Data Curation, Writing-Original Draft, Writing - Review & Editing, Visualization

Nipun Malhotra: Investigation, Methodology, Software, Formal Analysis, Data Curation, Writing - Review & Editing

Juan Ignacio Elio Mariángelo: Investigation, Methodology, Software, Formal Analysis, Data Curation, Writing - Review & Editing

Tyler L. Stevens: Methodology, Software, Validation, Investigation, Data Curation, Writing - Review & Editing

Lindsay J. Young: Methodology, Software, Validation, Investigation, Data Curation, Writing - Review & Editing

Steve Antwi-Boasiako: Methodology, Software, Validation, Investigation, Data Curation, Writing - Review & Editing

Danielle Abdallah: Investigation, Data Curation, Writing - Review & Editing

Sarah Sumie Takenaka: Investigation, Data Curation, Writing - Review & Editing

Omer Cavus: Investigation, Data Curation, Writing - Review & Editing

Nathaniel P. Murphy: Methodology, Writing - Review & Editing

Mei Han: Investigation, Writing - Review & Editing

Xianyao Xu: Investigation, Writing - Review & Editing

Matteo E. Mangoni: Methodology, Data Curation, Writing - Review & Editing, Funding Acquisition

Thomas J. Hund: Data Curation, Writing - Review & Editing, Funding Acquisition


Jason D. Roberts: Methodology, Data Curation, Writing-Original Draft, Writing - Review & Editing, Visualization

Sandor Györke: Methodology, Data Curation, Formal analysis, Writing - Review & Editing, Visualization

Peter J. Mohler: Conceptualization, Supervision, Project administration, Funding acquisition, Writing-Original Draft, Writing - Review & Editing, Visualization

Mona El Refaey: Conceptualization, Supervision, Project administration, Methodology, Formal analysis, Data Curation, Writing-Original Draft, Writing - Review & Editing, Visualization

[Click here to view linked References](#)



[Click here to access/download](#)

Revised Manuscript (with tracked changes)
E1458G May 2023.docx

